NCT05929651: A reported trial by Sanofi Pasteur, a Sanofi Company
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05929651 |
|---|---|
| Title | A Descriptive, Phase IV, Open-label, Single-arm Multi-center Study to Assess the Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Healthy Toddlers 12 to 23 Months of Age Who Had Been Primed With at Least 1 Dose of Another Quadrivalent Meningococcal Conjugate Vaccine, ie, Nimenrix® (MCV4-TT) or Menveo® (MCV4-CRM), in Infancy. |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 7, 2023 |
| Completion date | Sept. 9, 2024 |
| Required reporting date | Sept. 9, 2025, midnight |
| Actual reporting date | Aug. 29, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |